Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.55
+3.1%		$9.12
$6.00
▼
$11.22
$2.12B0.555.65 million shs2.31 million shs
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$14.91
+5.6%		$16.77
$8.72
▼
$27.41
$524.47M1.27561,674 shs347,149 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.10
-0.1%		$34.82
$20.65
▼
$43.25
$2.04B-2.46802,576 shs754,989 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.70
+5.2%		$10.47
$4.82
▼
$12.00
$1.88B1.592.36 million shs1.97 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+3.14%+4.65%-2.95%-18.18%+17.45%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+5.59%+4.12%-25.41%-14.01%+23.63%
Pharvaris N.V. stock logo
PHVS
Pharvaris
-0.06%-0.29%-17.59%-11.32%+35.34%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+5.22%+4.74%+8.23%+17.47%+93.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$8.55
+3.1%		$9.12
$6.00
▼
$11.22
$2.12B0.555.65 million shs2.31 million shs
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$14.91
+5.6%		$16.77
$8.72
▼
$27.41
$524.47M1.27561,674 shs347,149 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$31.10
-0.1%		$34.82
$20.65
▼
$43.25
$2.04B-2.46802,576 shs754,989 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$11.70
+5.2%		$10.47
$4.82
▼
$12.00
$1.88B1.592.36 million shs1.97 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
+3.14%+4.65%-2.95%-18.18%+17.45%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+5.59%+4.12%-25.41%-14.01%+23.63%
Pharvaris N.V. stock logo
PHVS
Pharvaris
-0.06%-0.29%-17.59%-11.32%+35.34%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
+5.22%+4.74%+8.23%+17.47%+93.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.50
Moderate Buy$20.50139.77% Upside
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.00
Buy$32.40117.30% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
2.80
Moderate Buy$58.6088.42% Upside
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.67
Moderate Buy$21.8686.81% Upside

Current Analyst Ratings Breakdown

Latest CBIO, BCRX, PHVS, and VIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$20.00 ➝ $22.00
10/6/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$60.00
10/6/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/6/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$36.00
10/6/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
10/2/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$12.00 ➝ $13.00
9/28/2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy
9/22/2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Sell (D-)
9/14/2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$65.00
9/14/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$27.00
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$874.84M2.50$1.28 per share6.70($0.57) per share-15.00
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10.84M51.08N/AN/A$14.32 per share1.04
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$4.71 per shareN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$68.56M28.88N/AN/A$5.50 per share2.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$263.86M-$1.50N/A12.39N/A-40.90%-86.89%66.37%11/2/2026 (Estimated)
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$153.94M-$6.72N/AN/AN/AN/A-101.50%-86.86%11/5/2026 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$198.79M-$3.05N/AN/AN/AN/A-61.40%-56.00%11/11/2026 (Estimated)
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$437.99M-$1.86N/AN/AN/AN/A-29.99%-23.62%11/4/2026 (Estimated)

Latest CBIO, BCRX, PHVS, and VIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026N/A
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.6739N/AN/AN/A$0.36 millionN/A
11/4/2026Q3 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.7393N/AN/AN/A$0.87 millionN/A
11/2/2026Q3 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.0903N/AN/AN/A$165.67 millionN/A
8/12/2026Q2 2026
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.7467-$0.81-$0.0633-$0.80N/AN/A
8/5/2026Q2 2026
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$0.1542$0.30+$0.1458$0.30$183.28 million$218.25 million
8/5/2026Q2 2026
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$0.3326$0.47+$0.1374$0.47$135.88 million$238.95 million
7/30/2026Q2 2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.7357-$0.74-$0.0043-$0.74$0.36 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.32
2.29
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.66
9.66
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
11.94
11.94
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.04
6.04

Institutional Ownership

CompanyInstitutional Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
3.80%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
24.84%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
435255.54 million245.83 millionOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4437.14 million27.92 millionNo Data
Pharvaris N.V. stock logo
PHVS
Pharvaris
14865.41 million57.66 millionNot Optionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
367169.22 million164.31 millionOptionable

Recent News About These Companies

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - What's Next?
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105412
Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-hits-new-52-week-high-heres-what-happened-2026-10-10/
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
October 9 at 6:47 PM  |  targetedonc.comT
Chutes & Ladders—Vir looks to Liu to lead late-stage push
October 9 at 6:47 PM  |  fiercebiotech.comF
Vir Biotechnology stock hits 52-week high at 11.96 USD
October 9 at 6:47 PM  |  ca.investing.comhttps://ca.investing.com/news/stock-market-news/vir-biotechnology-stock-hits-52week-high-at-1196-usd-93CH-4873947
Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% - Here's Why
October 9 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-shares-climb-61-heres-why-2026-10-09/
Vir Biotechnology, Inc. Announces Appointment of David Liu as Executive Vice President and Chief Medical Officer, Effective October 12, 2026
October 9 at 8:46 AM  |  marketscreener.comM
Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of ...
October 9 at 8:46 AM  |  marketscreener.comM
Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer
October 9 at 8:46 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vir-biotechnology-apos-vir-5500-134318305.html
What is HC Wainwright's Forecast for VIR FY2028 Earnings?
October 9 at 6:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-hc-wainwrights-forecast-for-vir-fy2028-earnings-2026-10-09/
HC Wainwright Forecasts Strong Price Appreciation for Vir Biotechnology (NASDAQ:VIR) Stock
October 9 at 2:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101787
Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What Happened
October 8 at 12:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vir-biotechnology-nasdaq-vir-shares-down-65-heres-what-happened-2026-10-08/
How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative
October 8 at 7:42 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/upcoming-solstice-phase-2-hdv-061350506.html
Vir Biotechnology (NASDAQ:VIR) Stock Rating Lowered by Zacks Research
October 8 at 6:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099308
Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research
October 8 at 6:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vir-biotechnology-nasdaq-vir-cut-to-strong-sell-at-zacks-research-2026-10-08/
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Financial Survey
October 8 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098823
Vir Biotechnology stock gained 5.46 percent before SOLSTICE data
October 7 at 11:40 AM  |  ad-hoc-news.deA
Vir Biotechnology appoints David Liu as chief medical officer
October 7 at 11:40 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4650956-vir-biotechnology-appoints-david-liu-as-chief-medical-officer
Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright
October 7 at 10:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-vir-biotechnology-nasdaq-vir-given-new-2200-price-target-at-hc-wainwright-2026-10-07/
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
October 5, 2026  |  marketscreener.comM
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026
October 5, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261005191358/en/vir-biotechnology-to-present-expanded-phase-2-solstice-results-for-elebsiran-and-tobevibart-in-hepatitis-delta-at-aasld%e2%80%99s-the-liver-meeting%c2%ae-2026/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.55 +0.26 (+3.14%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$8.50 -0.05 (-0.58%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$14.91 +0.79 (+5.59%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$14.88 -0.03 (-0.17%)
As of 10/9/2026 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$31.10 -0.02 (-0.06%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$32.25 +1.15 (+3.70%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$11.70 +0.58 (+5.22%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$11.62 -0.08 (-0.67%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas